Actually a good chart position / funadmentals
iBorrowdesk.com the short fee just doubled from 17 to 35 past 15 minutes.
News 15 min ago :
businesswire.com/news/home/20210405005386/en/Published-Peer-Reviewed-Data-Demonstrate-Bamlanivimab’s-High-Potency-Against-SARS-CoV-2-and-Support-its-Use-as-a-Foundational-Antibody-Therapy-to-Treat-and-Prevent-COVID-19/
- Study was the first of its kind to show a neutralizing antibody can decrease SARS-CoV-2 viral shedding and transmission by blocking virus replication in the upper airway
- Bamlanivimab moved from first screen to clinical testing in 90 days1 and is the world's first monoclonal antibody specifically developed against SARS-CoV-2 to receive FDA Emergency Use Authorization (EUA)2
iBorrowdesk.com the short fee just doubled from 17 to 35 past 15 minutes.
News 15 min ago :
businesswire.com/news/home/20210405005386/en/Published-Peer-Reviewed-Data-Demonstrate-Bamlanivimab’s-High-Potency-Against-SARS-CoV-2-and-Support-its-Use-as-a-Foundational-Antibody-Therapy-to-Treat-and-Prevent-COVID-19/
- Study was the first of its kind to show a neutralizing antibody can decrease SARS-CoV-2 viral shedding and transmission by blocking virus replication in the upper airway
- Bamlanivimab moved from first screen to clinical testing in 90 days1 and is the world's first monoclonal antibody specifically developed against SARS-CoV-2 to receive FDA Emergency Use Authorization (EUA)2
Trade active
Traded this at 27.20Trade closed manually
Sold at 31.10
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.